A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyDifferentiating mTOR inhibitors in renal cell carcinomaPredicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsChemoresistance and targeted therapies in ovarian and endometrial cancersEndometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasTemsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancerEffect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinomaMorphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinomaFulvestrant for the treatment of endometrial cancer.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Cancer-associated fibroblasts promote proliferation of endometrial cancer cellsPhase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyPhase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genesHigh frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stabilityPreclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.Current trends in targeted therapies for glioblastoma multiformeSpinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.Personalized therapy in endometrial cancer: challenges and opportunities.Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.The genomics and genetics of endometrial cancer.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Metabolic complications with the use of mTOR inhibitors for cancer therapyNew candidate therapeutic agents for endometrial cancer: potential for clinical practice (review).Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowRidaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. BroaddusmTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injuryEverolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.Personalized care in uterine cancer.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyRecent Advances in Endometrial Cancer.A Review of mTOR Pathway Inhibitors in Gynecologic CancerA genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition
P2860
Q21198871-C9214E39-B696-49B0-AF61-E881EC6E54FAQ26860172-CBD3B33B-A983-4176-A6AB-A28F8462C0F2Q27851999-FB089BB4-A209-458E-99F2-4556FA9A3E5EQ27853244-E09A05AC-C366-4C58-9642-59503AD9FD91Q28073246-F54B8C3E-3CBE-494E-BB08-BB6D5578C6F2Q28074769-1BBD5257-3136-4E2E-B4A5-C1C226E21061Q30407709-A8BB71DA-4A74-40F9-A24E-B430760BA375Q33442539-B1D599B1-F510-4C5A-8A94-E72525B2C89EQ33689293-318D741B-967F-402F-AED7-6D7AC105A0D2Q34306540-353BFBBC-EB62-4587-B83A-A54DE4B2382FQ34393036-1B93C31E-FDF0-4420-BD20-EC8FEC115718Q34467210-670A3A50-11B9-4527-A31A-1C0D04287A13Q34514391-A2D78832-A891-4120-9223-96D445D8E71EQ34571141-AF4B1F05-E302-4257-83D5-769D5A7305E0Q34781699-941E292F-5924-4F0C-811A-CC6E0CF0F87AQ34901877-27C460FA-116D-48E3-9A52-46A36C24CEB9Q35023418-315F7916-4E36-41C6-A272-39A09DDCEEE9Q35144264-B14B4827-9F2D-45A1-8DA8-4A01623E8B78Q35160677-504C5CEB-AF72-4377-A72F-CD835627CB77Q35275603-A1643D7C-E92C-4933-9BB3-96165A36ED6DQ35589601-40D07B48-226D-4099-8C05-2B50A64AE39FQ35864226-1889D535-0762-4515-B372-A9DCF168B7C9Q35874744-64B910AC-81FE-4914-BD6A-1A2ABC9434D1Q35911350-CAFA42D8-5470-4742-8CF2-088BE5679684Q35926060-CB795993-41F3-4D15-9826-108B80C31203Q36151896-37034B18-945E-4632-BF6D-E3F174B85D49Q36418630-EFB76517-FE10-4FF0-9678-E99EDA4850E6Q36553511-A45C0451-044D-49EF-8205-AD58EE43612FQ36553517-22532A4E-3569-4CE7-9F7A-7C82C281A3C0Q36684551-3F267F7A-1E1B-40CF-AE85-9DE81DDE9726Q36731185-72DB9A65-4A58-4F82-A77D-DAFEAA1A345AQ36746785-8E4E4005-86C9-471F-A11E-5CFCE7AABDB9Q36841899-69E47253-BD89-47D9-AA8B-3D487907DFB8Q36843926-B1140646-4615-49A4-A7FA-C5F5887494AAQ36857470-20AF812E-21BD-4804-97C0-FA4F6E733F61Q37006856-358ABEE2-B39B-4817-8040-7BCA40787E53Q37429034-2DEECB86-AFD7-4BE2-8381-644AE19DB990Q37620470-39ABB37D-AE0C-420E-865E-356B561CB23FQ37668889-059FC74B-282D-4E84-9F36-8FC6E2C04C88Q37695840-97FE3E5B-C47F-4DEA-AA92-B0F4DC4F2D73
P2860
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@en
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@nl
type
label
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@en
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@nl
prefLabel
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@en
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
A phase 2 study of the oral ma ...... current endometrial carcinoma.
@en
P2093
Brian M Slomovitz
Cheryl Walker
David M Gershenson
Judith Wolf
Karen H Lu
Lois M Ramondetta
Mark Munsell
Robert L Coleman
Russell R Broaddus
Taren Johnston
P2860
P304
P356
10.1002/CNCR.25515
P407
P577
2010-08-02T00:00:00Z